Comparing the current results to its competitors, Bioatla Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Bioatla Inc 's competitors' average revenue growth of 9.7 %, achieved in the same quarter.
Bioatla Inc 's Comment on Competition and Industry Peers
The biotechnology and biopharmaceutical industries, including the oncology subsector, are characterized by rapid evolution, strong competition, and intellectual property challenges. The company holds a patented technology platform and expertise that it considers competitive advantages. However, it faces potential competition from large biopharmaceutical companies, specialty biotechnology firms, and academic research departments. Competitors are developing antibody therapies in immuno-oncology and immune-based cellular therapies for oncology. Approved products may compete with existing biologics and small molecule therapies or be used in combination with them. Competitors may possess greater financial resources, research and development expertise, manufacturing capabilities, clinical trial experience, regulatory approval success, and marketing strength. Ongoing merger and acquisition activity may consolidate resources among fewer competitors. Competition also exists in recruiting personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. Smaller or early-stage companies may also represent significant competition.
July 17, 2025
In the realm of biotechnology and oncology, significant advancements are continually being developed to tackle the complex nature of cancer. BioAtla, Inc., a clinical-stage biotechnology company based in San Diego, stands at the forefront of this innovative frontier. Focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, BioAtla is committed to revolutionizing the treatment of solid tumors, a category of cancers known for their challenging prognosis.Recently, BioAtla announced an upcoming oral presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting, which will take place in Hong Kong from July 18 to 20, 2025. The ESMO TAT Asia Meeting is a pres...
December 16, 2024
In the realm of oncology, few challenges have been as vexing as the treatment of non-small cell lung cancer (NSCLC), particularly in patients harbouring mutations in the KRAS gene. At the recent IASLC 2024 Hot Topic in Basic and Translational Science Meeting, BioAtla Inc. (NASDAQ: BCAB) unveiled compelling data highlighting the clinical outcomes of their investigational drug, Mecbotamab Vedotin (Mec-V), particularly in the subset of patients with treatment-refractory NSCLC characterised by a mutated KRAS genotype.KRAS mutations, notorious for their role in driving oncogenesis, have long posed a significant barrier to effective treatment. These mutations are present in approximately 25-30% of NSCLC cases and ...
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Xencor Inc is a biotechnology company that primarily focuses on the development of therapeutic antibodies. Their business model revolves around utilizing their proprietary XmAb® technology to engineer antibodies with enhanced properties for the treatment of various diseases. They collaborate with pharmaceutical companies to develop and commercialize these antibody therapeutics, generating revenue through upfront payments, milestone payments, and royalties.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Sources:
Bioatla Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bioatla Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
